-
1年经验
-
招2人
-
11-09 发布
职位描述
泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。 Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al. 视 频 资 料 http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
联系方式
泰州医药高新技术产业园
公司信息
泰州迈博太科药业有限公司于2015年入驻泰州市中国医药城,注册资本2000万美元。公司主要从事单抗药物生产,投资总额2亿美元,拟建厂房面积3万余平方,建设符合GMP标准的国际先进的抗体药物制备体系,以期打造国内抗体药物生产高地。迈博太科药业由上海张江生物技术有限公司(抗体药物与靶向治疗国家重点实验室)抗体研发团队提供一站式平台服务,致力于实现一系列重量级国家创新抗体药物的产业化。现有品种:治疗结直肠癌的重组抗EGFR人鼠嵌合单克隆抗体,治疗银屑病的重组人LFA3-抗体融合蛋白等。 Taizhou Mabtech Pharmaceutical Co., Ltd. joined the China Medical City (CMC) in 2015 with registered capital of USD 20 million, expanding a national highland for monoclonal antibody medicine manufacturing by establishing internationally advanced antibody medicine manufacture system with adopted cGMP standards, with a total investment of USD 200 million. Supported by the one-stop platform for therapeutic mAb medicine development provided by ZJ-Bio R&D Team (State Key Laboratory of Antibody Medicine and Targeted Therapy), Taizhou Mabtech Pharmaceutics Co., Ltd is dedicated to industrialization of a series of “blockbuster” innovative antibody drugs. Existing varieties: recombinant anti-EGFR human/mouse-chimeric monoclonal antibody for the treatment of colorectal cancer, recombinant human LFA3-antibody fusion protein for the treatment of psoriasis , et al. 视 频 资 料 http://www.tz2100.com/news/dqxw/gx/2015/4/9/1428544031298.shtml
泰州相关职位
-
设备维护担当 6-8千/月
-
设施/公用系统验证专员 3-4.5千/月
-
验证测试工程师 3-7千/月
-
QC仪器分析主管 0.5-1万/月
-
商务员J11092 6-8千/月
-
QA巡检员J11093 4.5-6千/月
-
临床稽查员 5-8千/月
-
验证管理员J11095 4.5-6千/月
-
包装工 4-6千/月
-
区域产品经理J11096 0.8-1万/月
-
医学监察员(Medical Montior) 0.6-1万/月
-
医学写作(Medical Writor) 0.6-1万/月
-
LC-MS/MS分析高级研究员/研究员 0.8-1.2万/月
-
工艺员J10401 4.5-6千/月